Psyence Biomedical Ltd. has completed its $2.6 million investment in Psyence Labs after achieving key milestones including regulatory readiness documentation for ibogaine and a manufacturing agreement with DEA-registered Benuvia in Texas. This supports the planned US development of pharmaceutical-grade ibogaine, with PsyLabs focusing on supply and Texas Ibogaine Research Corporation handling manufacturing and regulatory work. The investment increases Psyence BioMed's stake in PsyLabs to over 43%, advancing their neuroplastogen-based mental health treatment program.
Psyence BioMed's recent investment in PsyLabs provides context for health-sector trading activity on Pluang. For readers following the health sector, here is Pluang's market snapshot as of Oct 21, 2026 17:11 WIB: Out of 150 priced US health stocks, 77 rose and 61 fell today. Inovio Pharmaceuticals Inc (INO) rose 2.97% to USD 1.04 with 100% sell order activity and a typical hold time of 43 days, contrasting with BioNano Genomics Inc (BNGO) which fell 2.81% to USD 1.21 and also saw 100% sell orders but a longer hold time of 51 days. Nuvation Bio Inc. (NUVB) increased 2.94% to USD 4.91 with a shorter typical hold time of 12 days.
The Human Feedback Foundation, supported by RBC, has launched the Agentic AI Design Exchange, a national program aimed at helping Canadian nonprofits design, build, and deploy AI agents responsibly. Funded through RBC's Stronger Nonprofits Program, t...
Satellos Bioscience Inc., a clinical-stage company focused on treatments for degenerative muscle diseases, announced its management will participate in two investor conferences in November: the Guggenheim Healthcare Innovation Conference on Nov 9 in ...
YYForce Inc. has purchased 20 wearable data collection systems to gather real task data from hotel room service at Novotel Singapore. This project aims to record and analyze experienced staff performing tasks like bed-making, towel folding, and clean...
The global digital health and remote patient monitoring market is projected to grow from $26.8 billion in 2025 to $80.8 billion by 2031, at a compound annual growth rate of 20.2%. This growth is driven by increasing demand for chronic disease managem...
The global private credit and alternative lending market, valued at $2.31 trillion in 2026, is expected to grow at a 7.8% CAGR to reach $3.36 trillion by 2031. Recent liquidity pressures in 2025, triggered by bankruptcies and AI sector concerns, caus...
